[HTML][HTML] Phase 1b study of sintilimab plus anlotinib as first-line therapy in patients with advanced NSCLC

T Chu, R Zhong, H Zhong, BO Zhang, W Zhang… - Journal of Thoracic …, 2021 - Elsevier
Introduction Although the interaction between tumor immune microenvironment and
angiogenesis has been well established, evidence supporting the chemo-free combination …

[PDF][PDF] Phase 1b Study of Sintilimab Plus Anlotinib as First-line Therapy in Patients With Advanced NSCLC

T Chu, R Zhong, H Zhong, B Zhang… - Journal of Thoracic …, 2020 - researchgate.net
Introduction: Although the interaction between tumor immune microenvironment and
angiogenesis has been well established, evidence supporting the chemo-free combination …

Phase 1b Study of Sintilimab Plus Anlotinib as First-line Therapy in Patients With Advanced NSCLC.

T Chu, R Zhong, H Zhong, B Zhang… - Journal of Thoracic …, 2021 - europepmc.org
Methods Eligible patients who were treatment-naive and had unresectable stage IIIB/C or IV
NSCLC without EGFR/ALK/ROS1 mutations received sintilimab (200 mg, day 1) and …

Phase 1b Study of Sintilimab Plus Anlotinib as First-line Therapy in Patients With Advanced NSCLC

T Chu, R Zhong, H Zhong, B Zhang… - Journal of thoracic …, 2021 - pubmed.ncbi.nlm.nih.gov
Introduction Although the interaction between tumor immune microenvironment and
angiogenesis has been well established, evidence supporting the chemo-free combination …

Phase 1b Study of Sintilimab Plus Anlotinib as First-line Therapy in Patients With Advanced NSCLC

T Chu, R Zhong, H Zhong, B Zhang, W Zhang… - Journal of Thoracic …, 2021 - jto.org
Introduction Although the interaction between tumor immune microenvironment and
angiogenesis has been well established, evidence supporting the chemo-free combination …